Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGL-2102
- Development stage
- Unknown
- Lead developer
- Center for Addiction and Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
MAGL-2102 is a novel, reversible monoacylglycerol lipase (MAGL) inhibitor developed as a positron emission tomography (PET) radiotracer (typically labeled as [18F]MAGL-2102) for in vivo neuroimaging of MAGL. MAGL is a key enzyme in the endocannabinoid system that degrades 2-arachidonoylglycerol (2-AG) into arachidonic acid, a precursor for proinflammatory eicosanoids. While preclinical studies in rodents and non-human primates showed promising brain uptake and specific binding, a first-in-human PET study demonstrated low brain penetration and high plasma protein binding in humans, suggesting that MAGL-2102 may have limited utility for reliable brain imaging of MAGL in clinical settings.
- Other names
- [18F]MAGL-2102
02
Targets
MGLL (Monoacylglycerol lipase)
Beyond the preview
Go deeper on MAGL-2102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGL-2102.